ABT
Abbott just added another screening weapon
Abbott rolled out SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45 and older at average risk. In plain English: the company now has a blood option alongside its stool-based screening product, which is a pretty nice way to say, “we’d like doctors to have fewer excuses not to screen people.”
Why this matters
The launch isn’t just a shiny product headline. Abbott says it’s the only company offering an end-to-end screening solution with both stool- and blood-based options, and SimpleScreen CRC is covered by Medicare for eligible patients with Part B. That matters because reimbursement is the boring superpower of healthcare — the part that turns a cool lab result into an actual business.
The bigger play
If you’re Abbott, the goal is obvious: make colorectal screening easier to adopt, reach people who otherwise stay unscreened, and widen the moat in diagnostics. Blood-based screening could be a gentler, more convenient option for patients who’d rather do almost anything else than a stool test.
- Adult screening pool: 45+ average-risk patients
- Coverage: Medicare, no out-of-pocket cost for eligible patients with Part B
- Strategic angle: more screening options can mean more testing volume
Big picture: Abbott isn’t just selling a test here — it’s trying to make screening feel less like a chore and more like a default choice. And in healthcare, defaults are where the money tends to hide.